Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2004-03-29
2010-06-08
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100
Reexamination Certificate
active
07731971
ABSTRACT:
The present invention provides peptides and proteins for use in second generation HIV vaccines and as diagnostic tools in the treatment and control of HIV infection. The antiviral protection shown by compositions of the present invention has not been previously achieved with an HLA epitope-enhanced vaccine. These findings define a critical balance between MHC affinity and receptor crossreactivity required for effective epitope enhancement and also demonstrate construction and efficacy of such a component of a new generation vaccine.
REFERENCES:
patent: 6133418 (2000-10-01), Bolognesi et al.
patent: 6534483 (2003-03-01), Bruno et al.
patent: WO 99/51750 (1999-04-01), None
Leslie, A. J., et al., 2004, HIV evolution: CTL escape mutation and reversion after transmission, Nat. Med. 10(3):282-289.
Johnson, P. R., et al., 1992, Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation, J. Exp. Med. 175:961-971.
Feinberg, M. B., et al., 2002, AIDS vaccine models: challenging challenge viruses, Nat. Med. 8(3):207-210.
Letvin, N. L., et al., 2003, Immunopathogenesis and immunotherapy in AIDS virus infections, Nat. Med. 9(7):861-866.
Yang, O. O., et al., 2003, Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL, J. Immunol. 171:3718-3724.
Connick, E., et al., 2007, CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue, J. Immunol. 178:6975-6983.
Sarobe, P., et al., 1998, Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement as secondary HLA-A2.1 binding positions, J. Clin. Invest. 102:1239-1248.
Berzofsky, J. A., et al., 1999, Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections, Immunol. Rev. 170:151-172.
Berzofsky, J. A., et al., Strategies for designing and optimizing new generation vaccines, Nat. Rev. Immunol. 1:209-219.
Herrer, E., et al., 1996, Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor, J. Infect. Dis. 173:476-479.
van der Burg, Sjoerd, et al., “Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules,”Journal of Immunology(1999) 162: 152-160.
Berzofsky, Jay A. et al.; “Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections”; 1999,Immunological Reviews, vol. 170, pp. 151-172.
Firat, Huseyin et al.; “Design of a polyepitope construct for the induction of HLA-A0201-restricted HIV 1-specific CTL responses usingHLA-A*0201transgenic,H-2class 1 KO mice”; 2001,Eur. J. Immunol., vol. 31, pp. 3064-3074.
Harrer, Ellen et al.; “Recognition of the Highly Conserved YMDD Region in the Human Immunodeficiency Virus Type 1 Reserve Transcriptase by HLA-A2-Restricted Cytotoxic T Lymphocytes from an Asymptomatic Long-Term Nonprogressor Cytotoxic T Lymphocytes from an Asymptomatic Long-Term Nonprogressor”; 1996,The Journal of Infectious Diseases, vol. 173, pp. 476-479.
Okazaki, Takahiro et al.; “Epitope-Enhanced Conserved HIV-1 Peptide Protects HLA-A2-Transgenic Mice Against Virus Expressiong HIV-1 Antigen”; 2003,The Journal of Immunologists, pp. 2548-2555.
Pascolo, Steve et al.; “HLA-A2.1-restricted Education and Cytolytic Activity of CD8+T Lymphocytes from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Dbβ2m Double Knockout Mice”; 1997,J. Exp. Med., vol. 185, No. 12, pp. 2043-2051.
Rammensee, Hans Georg; “MHC ligands and peptide motifs: first listing”; 1995,Immunogenetics, vol. 41, pp. 178-228.
Berzofsky Jay A.
Okazaki Takahiro
Parkin Jeffrey S.
The United States of America as represented by the Secretary of
Townsend and Townsend / and Crew LLP
LandOfFree
Enhanced CTL epitope-containing HIV-1 reverse transcriptase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhanced CTL epitope-containing HIV-1 reverse transcriptase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced CTL epitope-containing HIV-1 reverse transcriptase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199217